Category Archives: Adult Stem Cells


Stem Cell Banking Market was valued at $1986 million in 2016 – Markets Gazette

A fresh report titled Stem Cell Banking Market has been presented by KD market insights. It evaluates the key market trends, advantages, and factors that are pushing the overall growth of the market. The report also analyzes the different segments along with major geographies that have more demand for Stem Cell Banking Market. The competition analysis is also a major part of the report.

The global stem cell banking market was valued at $1,986 million in 2016, and is estimated to reach $6,956 million by 2023, registering a CAGR of 19.5% from 2017 to 2023. Stem cell banking is a process where the stem cell care isolated from different sources such as umbilical cord and bone marrow that is stored and preserved for future use. These cells can be cryo-frozen and stored for decades. Private and public banks are different types of banks available to store stem cells.

Request for Sample @ https://www.kdmarketinsights.com/sample/3947

Increase in R&D activities in regards with applications of stem cells and increase in prevalence of fatal chronic diseases majorly drive the growth of the global stem cell banking market. Moreover, the large number of births occurring globally and growth in GDP & disposable income help increase the number of stem cell units stored, which would help fuel the market growth. However, legal and ethical issues related to stem cell collections and high processing & storage cost are projected to hamper the market growth. The initiative taken by organizations and companies to spread awareness in regards with the benefits of stem cells and untapped market in the developing regions help to open new avenues for the growth of stem cell banking market in the near future.

The global stem cell banking market is segmented based on cell type, bank type, service type, utilization, and region. Based on cell type, the market is classified into umbilical cord stem cells, adult stem cells, and embryonic stem cells. Depending on bank type, it is bifurcated into public and private. By service type, it is categorized into collection & transportation, processing, analysis, and storage. By utilization, it is classified into used and unused. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.

The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.

In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.

The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Cell Type

Umbilical Cord Stem Cell

Cord Blood

Cord Tissue

Placenta

Adult Stem Cell

Embryonic Stem Cell

By Bank Type

Public

Private

By Service Type

Collection & Transportation

Processing

Analysis

Storage

By Utilization

Used

Unused

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific

Japan

China

Singapore

India

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

KEY PLAYERS PROFILED

Cord Blood Registry

ViaCord

Cryo-Cell

China Cord Blood Corporation

Cryo-Save

New York Cord Blood Program

CordVida

Americord

CryoHoldco

Vita34

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/stem-cell-banking-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description1.2. Key benefits for stakeholders1.3. Key market segments1.4. Research methodology

1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope3.2. Key findings

3.2.1. Top investment pockets3.2.2. Top winning strategies

3.3. Porters five forces analysis3.4. Top Player Positioning3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Large number of newborns3.5.1.2. Increase in R&D activities for application of stem cells3.5.1.3. Increase in prevalence of fatal chronic diseases3.5.1.4. Growth in GDP and disposable income

3.5.2. Restraints

3.5.2.1. Legal and ethical issues during collection of stem cells3.5.2.2. High processing and storage cost3.5.2.3. Lack of acceptance and awareness

3.5.3. Opportunities

3.5.3.1. Initiatives to spread awareness3.5.3.2. Untapped market in developing regions

CHAPTER 4: STEM CELL BANKING MARKET, BY CELL TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Umbilical Cord Stem Cells

4.2.1. Key market trends and growth opportunities4.2.2. Market size and forecast4.2.3. Market analysis, by country4.2.4. Cord Blood

4.2.4.1. Market size and forecast

4.2.5. Cord Tissue

4.2.5.1. Market size and forecast

4.2.6. Placenta

4.2.6.1. Market size and forecast

4.3. Adult stem cells

4.3.1. Key market trends and growth opportunities4.3.2. Market size and forecast4.3.3. Market analysis, by country

4.4. Embryonic stem cells

4.4.1. Key market trends and opportunities4.4.2. Market size and forecast4.4.3. Market analysis, by country

Continue

Check for Discount @https://www.kdmarketinsights.com/discount/3947

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Continue reading here:
Stem Cell Banking Market was valued at $1986 million in 2016 - Markets Gazette

Republicans demand answers about government experiments with animals and fetal tissue – Washington Examiner

Republican lawmakers are demanding the Trump administration provide more information about government experiments that mix animals with fetal tissue from abortions.

In a letter sent Wednesday, 69 lawmakers said they were "disappointed" the research had been allowed to continue and highlighted a Washington Examiner op-ed from August that said the National Institutes of Health, the government's research branch, paid out $115 million for 200 different projects involving fetal tissue.

The op-ed was written by Terrisa Bukovinac, founder and executive director of Pro-Life San Francisco, and by Alyssa Canobbio Hackbarth, a board member for an anti-animal experimentation group called the White Coat Waste Project. They describe experiments in which scientists were "implanting thymus glands from aborted human babies into mice" and "dissecting kidney tissue from 8 to 18-week-old human fetuses."

The Republicans asked Alex Azar, the Health and Human Services secretary, to send more information about the grants and what fetal parts they use, and about which ones also used animals. They also asked for more information about the ethics board the NIH said it would create to devise a system for reviewing grants that involve the tissue.

The NIH announced in June that it would no longer let government scientists conduct experiments using any new fetal tissue acquired from abortions. It did not, however, put a stop to the research already underway or stop outside groups that receive the funding from conducting the research.

The decision came after months of backlash from anti-abortion groups, who demanded President Trump fire NIH Director Francis Collins for saying that research using fetal tissue could provide useful study for treatments of devastating illnesses.

At the same time, some members of Congress are pressuring government agencies to look for alternatives to animal experimentation whenever possible. The Environmental Protection Agency has pledged not to use any mammals for research starting in 2035.

Still, animal experimentation is common. Any prescription drug that has been approved by the Food and Drug Administration first had to clear animal testing before scientists moved onto trials involving people.

Republicans have called for ending fetal tissue research since the anti-abortion Center for Medical Progress released videos that appeared to show Planned Parenthood staff discussing the sale of fetal tissue, a practice that is illegal. Planned Parenthood has denied wrongdoing, and state investigations have not found evidence that the organization illegally sold fetal tissue for profit.

Outside groups opposed to fetal tissue research are not just opposed to abortion, but contend the practice of using the tissue in experiments is degrading, wrong, and unnecessary. They question whether fetal tissue research is effectual and believe other types of tissues work better and should be used instead adult stem cells, umbilical cord, amniotic fluid, tissue from the placenta, or discarded tissue from surgery on an infant. Major medical groups defend the research and say fetal tissue has unique properties that will help scientists develop cures to infectious and chronic diseases.

View original post here:
Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner

The Other Side of Stem Cell Research – The Tablet Catholic Newspaper

(Photo: Getty Images)

By Christopher White, The Tablets National Correspondent

Last month, the federal government implemented a new ban on using fetal tissue for research a move praised by U.S. Catholic leaders.

Yet while the church has long opposed using fetal tissue for research, as it is often derived from abortions, many Catholics are largely unaware that the church supports the use of umbilical cord blood, which is rich in stem cells and has proven effective in many therapies.

Stem cells are special human cells, which can be developed into many types of cells. In 2001, President George W. Bush banned federal funding for embryonic stem cell research a move supported by Catholic leaders as it required the destruction of a human embryo.

Among the ethically acceptable alternatives supported by the church is that of adult stem cell research and using cord blood stem cell transplants, which has proven to be the best way of treating leukemia, sickle cell anemia, Hodgkin lymphoma and a range of other diseases.

In its 2000 document, Declaration on the Production and the Scientific and Therapeutic use of Human Embryonic Stem Cells, the church noted that such a practice offers a more reasonable and human method for making correct and sound progress in this new field of research and in the therapeutic applications which it promises.

These applications are undoubtedly a source of great hope for a significant number of suffering people, the document noted.

Five years later, Cardinal William Keeler, who was then chairman of the United States Conference of Catholic Bishops (USCCB), echoed those words and called for more federal funding to develop a nationwide bank for umbilical cord blood cells.

Umbilical cord blood stem cells have successfully treated thousands of patients with dozens of diseases, Cardinal Keeler said.

They also exhibit properties once associated chiefly with embryonic stem cells: They grow rapidly in culture, producing enough cells to be clinically useful in both children and adults; they can treat patients who are not an exact genetic match, without being rejected as foreign tissue; and they seem able to produce a wide array of different cell types.

What is preventing far broader use of umbilical cord blood stem cells is not an ethical concern, or any lack of evidence of clinical benefits, but simply a lack of funding and access, he lamented at the time.

Jennifer Lahl, a pediatric nurse for more than 20 years and president of the California-based Center for Bioethics and Culture, described the process for The Tablet.

When a baby is born in the hospital delivery room, the umbilical cord blood, which is rich in stem cells, is extracted and saved in a Cord Blood Bank until it is needed to treat a patient, Lahl said.

Parents can make the decision to do private cord blood banking to save the stem cells for use in their own family, but it is more often recommended to store the cord blood stem cells in a public bank, similar to our public blood banks. This makes the stems cells available to anyone who is a match and needs a stem cell transplant, she continued.

Cord blood stem cells are a wonderful resource that should not be tossed out after the delivery of a baby, but saved in order to one day save a life, she added.

Charles Camosy, a theology professor at Fordham University who specializes in medical ethics, noted that the Catholic Church has been a leading proponent of the use of cord blood and has even led the way in working with secular medical institutions to explore their potential.

The Catholic Church has been enthusiastically in support of stem cell research that does not involve embryo-destruction for many years now, he told The Tablet. Indeed, the Vatican has even formally partnered with companies like NeoStem, a U.S.-based biopharmaceutical firm, to see what adult stem cells can do to aid vulnerable sick and disabled people. It turns out, quite a bit. Many therapies have been produced via adult stem cells as well as stem cells from the amniotic fluid of pregnancy. In some cases, it has literally made the blind see.

Yet while developments have offered great promise, he cautioned to carefully discern which companies to use when engaging in treatment.

One should be careful not to be scammed by companies offering to freeze cord blood promising more than can be delivered, he advised. While we still may find new and even dramatic therapies from cord blood stem cells, much of the work has yet to be done.

In 2011, when the Vatican announced its partnership with NeoStem, CEO Dr. Robin Smith said such a partnership offered a way to alleviate human suffering by unlocking the healing power of the human body.

Most importantly, she added, we are able to do all this without destroying another human life.

Read the original post:
The Other Side of Stem Cell Research - The Tablet Catholic Newspaper

Reviewing MediciNova Inc. (MNOV)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

MediciNova Inc. (NASDAQ:MNOV) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows us MediciNova Inc. and Brainstorm Cell Therapeutics Inc.s net margins, return on assets and return on equity.

Risk and Volatility

A beta of 1.18 shows that MediciNova Inc. is 18.00% more volatile than Standard and Poors 500. Brainstorm Cell Therapeutics Inc. has a 1.19 beta and it is 19.00% more volatile than Standard and Poors 500.

Liquidity

The Current Ratio and Quick Ratio of MediciNova Inc. are 34.8 and 34.8 respectively. Its competitor Brainstorm Cell Therapeutics Inc.s Current Ratio is 1 and its Quick Ratio is 1. MediciNova Inc. can pay off short and long-term obligations better than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for MediciNova Inc. and Brainstorm Cell Therapeutics Inc.

Meanwhile, Brainstorm Cell Therapeutics Inc.s consensus price target is $9, while its potential upside is 127.85%.

Institutional and Insider Ownership

Roughly 21.3% of MediciNova Inc. shares are owned by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. About 2.7% of MediciNova Inc.s share are owned by insiders. Competitively, 0.6% are Brainstorm Cell Therapeutics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year MediciNova Inc.s stock price has bigger growth than Brainstorm Cell Therapeutics Inc.

Summary

MediciNova Inc. beats on 7 of the 11 factors Brainstorm Cell Therapeutics Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The companys product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a 2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side – MS Wkly

SI-BONE Inc. (NASDAQ:SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) compete with each other in the Medical Appliances & Equipment sector. We will analyze and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for SI-BONE Inc. and Cesca Therapeutics Inc.

Profitability

Table 2 shows SI-BONE Inc. and Cesca Therapeutics Inc.s return on equity, net margins and return on assets.

Liquidity

SI-BONE Inc. has a Current Ratio of 13.1 and a Quick Ratio of 12.7. Competitively, Cesca Therapeutics Inc.s Current Ratio is 1.6 and has 0.8 Quick Ratio. SI-BONE Inc.s better ability to pay short and long-term obligations than Cesca Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for SI-BONE Inc. and Cesca Therapeutics Inc.

Meanwhile, Cesca Therapeutics Inc.s consensus target price is $7.5, while its potential upside is 45.07%.

Insider & Institutional Ownership

The shares of both SI-BONE Inc. and Cesca Therapeutics Inc. are owned by institutional investors at 74.7% and 1.8% respectively. About 3% of SI-BONE Inc.s share are held by insiders. Insiders Comparatively, held 30.91% of Cesca Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year SI-BONE Inc. had bearish trend while Cesca Therapeutics Inc. had bullish trend.

Summary

SI-BONE Inc. beats on 7 of the 9 factors Cesca Therapeutics Inc.

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the United States and internationally. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood. The company also offers MarrowXpress system, a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; BioArchive system, an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use; and manual disposables bag sets for use in the processing and cryogenic storage of cord blood. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to see the original:
SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly

Inherited Learning? It Happens, but How Is Uncertain – Quanta Magazine

Rechavi says that exactly how the changes in the neurons are communicated to the germline and how thataffects the nervous system of the next generation are still open questions. He hypothesizes that the process involves one or more molecules released by the nervous system perhaps small RNAs, perhaps something secreted like a hormone. But somehow those germ cells then influence the behavior of the next generation and seem to circumvent the normal need for rde-4 in the production of the small RNAs for chemotaxis in the progeny.

In another paper on epigenetic behavior that appeared in the same June issue of Cell, Rebecca Moore, Rachel Kaletsky and Coleen Murphy, the molecular biologist who leads their laboratory at Princeton University, reported that C. elegans worms exposed to the pathogenic bacterium Pseudomonas aeruginosa learn to avoid it, and they transmit this learned avoidance for approximately four generations. Normally, the worms seem to prefer Pseudomonas to the bacteria on which they routinely feed.

The researchers sought to understand how this behavior is controlled at a molecular level. They discovered that double-stranded RNA from the pathogen triggered the worms response, a finding that they further investigated with Lance Parsons of Princeton University and described in a biorxiv preprint posted on July 11.

In the worms exposed to the pathogen, they detected changes in the expression of a gene, daf-7, in a specific neuron called ASI that is required for the avoidance behavior. They also found a huge number of changes in the small RNAs in the germline, Murphy said, including the ones called Piwi-interacting RNA (piRNA). As the name suggests, piRNAs interact with piwi genes, which help to regulate stem cell differentiation.

Moore, Kaletsky and Murphy found that animals without the piRNA pathway can learn to avoid Pseudomonas but do not pass on this avoidance behavior to their progeny. Thus, the piRNA pathway is critical for inheritance of the behavior. Thats why were excited about the piRNA pathway, Murphy said.

Sarkies thinks these findings may help to explain the curious ability of C. elegans to take up double-stranded RNA from the environment and use it to silence endogenous genes. For years, geneticists have exploited this property of worms: By synthesizing double RNAs that match any gene, researchers can silence it and study what it does.

But why the worm has this ability was mysterious. It obviously didnt evolve it in order to make life easy for scientists, and we dont really understand what ecological role it might have, Sarkies said. Whats quite exciting in principle about the studies from the Murphy lab is that they suggest that this might be a way in which C. elegans is able to adapt to pathogenic bacteria. Hypothetically, when the worm takes up double-stranded RNA from bacteria in its environment, the molecules could silence some of the worms genes and induce adaptive responses. Those adaptations could then be passed to the next generation.

Most in the field still approach such conjectures with skepticism. I believe that today, there is not a single solid paper showing that only small RNAs are involved in epigenetic inheritance, said Isabelle Mansuy, a neuroepigenetics researcher at the Swiss Federal Institute of Technology Zurich and the University of Zurich who studies the inheritance of trauma in humans and mice. In the mouse model she works with, she knows that small RNAs are not sufficient because if she injects small RNAs alone into fertilized mouse eggs, the resulting animals do not show the RNA-associated trait.

Mansuy believes that a multitude of factors may contribute in different ways to epigenetic inheritance, and their importance may vary with the trait or behavior. Very often people like to simplify the matter and think either its DNA methylation or its microRNA. I think its totally misleading to think that way, she said. People should not dismiss one or the other but just think about all these factors together.

She added that errors have crept into the literature on epigenetic inheritance, making some findings seem more definitive than they are. For example, some review articles claim that Mansuy demonstrated that injecting microRNAs into fertilized eggs is sufficient to cause the inheritance of behavioral symptoms in mice. We never showed this, she emphasized. Authors of review articles often dont go back to check the original findings, so when the review is cited subsequently, it creates an auto-feeding system that perpetuates errors. Its polluting the field, she said. Now many people work only on RNA epigenetic inheritance because they think it is well established, she added.

Unreliable findings have also sometimes appeared in high-profile journals. As a result, she argues, the field as a whole may be on thinner ice than it seems. The lack of rigor can lead to a misleading thought and perception, she warned.

Validation of Mansuys skepticism can be found in a recent study in eLife on epigenetic inheritance in fruit flies. Giovanni Bosco and his colleagues at Dartmouth College demonstrated that learned adaptive behaviors in fruit flies can be epigenetically inherited but that small RNAs are not sufficient to transmit this behavior.

In Drosophila, adult females raised with parasitic wasps learn to lay their eggs on food that contains ethanol, which protects the eggs and larvae from being parasitized by the wasps. This egg-laying preference occurs even when the mother herself was never exposed to ethanol, Bosco emphasized. Exposure to the wasp was in and of itself sufficient for the females to somehow epigenetically reprogram their eggs so that their daughters would be predisposed to have this behavior, he said.

The preference for egg laying on ethanol persists for five generations. Bosco, his graduate student Julianna Bozler, and Balint Kacsoh (now a postdoc at the University of Pennsylvania) hypothesized that small RNAs were involved in the inheritance of this behavior. To test this idea, they used a quirk of fly genetics to create flies with a pair of chromosomes that both came from the same parent (normally, both parents contribute to each pair). Boscos team reasoned that if small RNAs in the cytoplasm of the mothers egg were sufficient for inheritance of the learned behavior, then the offspring should exhibit the inherited behavior even if it received both pairs of chromosomes from the father.

In a series of experiments, Bozler, Kacsoh and Bosco demonstrated that small noncoding RNAs from the mother were not sufficient for transmitting the behavior between generations; an as yet unidentified epigenetic modification on chromosome 3 was also essential. They are currently investigating the nature of this epigenetic change.

To Bosco, the big question is: How does the signal from the brain reach an egg and change the information thats in the egg? Figuring this out would open the floodgates to ask: What else is the brain doing to the germline? What else are our cognitive experiences and environmental exposures impinging on the epigenome of the egg or sperm?

Most people, Bosco continued, would have no trouble accepting that exposure to a toxic chemical in our water or food could interact with the germline and change the epigenetic state of germ cells.

What I would suggest is that our brains are our pharmacies, Bosco said. Our brains are making chemicals all the time, such as neuropeptides and other neuromodulatory molecules with diverse functions. Some of those functions impinge directly on processes in other organs, including the reproductive system. If we can ingest a chemical from our environment that changes the epigenomes of the egg or sperm, why couldnt our brain make a similar molecule that does the same thing? he said.

At Cambridge, Burton has identified at least one of the ways in which information from the nervous system can be transmitted to the germline. In a 2017 Nature Cell Biology paper, he and his colleagues exposed C. elegans to high levels of salt to induce a state called osmotic stress. They discovered that the worms brain responded by secreting insulin-like peptides that change the egg-making cells (oocytes) in ways that induce an epigenetic change. The resulting alterations in gene expression in the oocytes lead the offspring to produce more glycerol, which protects them against osmotic stress.

You have a neuronal signal affecting the germ cells that looks to be adaptive, Burton said.

Mansuy has found that early-life trauma in mice leads to the release of stress hormones that affect the animal throughout its life span, producing depressed or risk-taking behaviors, metabolic dysregulation, and other health problems. They also affect the developing germ cells, causing the same behaviors and metabolic alterations to be inherited in the offspring for up to five generations. Previously, Mansuy had found that small RNAs were not sufficient to transmit these phenotypes in mice, just as they were not sufficient in the fruit flies. Something else was going on.

In a preprint recently posted on biorxiv.org, she and her colleagues report that by injecting the blood of traumatized mice into control mice, they could induce similar metabolic symptoms. The injected blood also appeared to affect the mices germ cells because their offspring inherited the metabolic abnormalities too.

The researchers identified some of the signaling molecules that transmitted the metabolic effects as fatty acids that can bind to receptor molecules, move into the nucleus and help activate the transcription of certain targeted genes. The receptors exist in germ cells, too, so they could be one of the ways in which information moves between blood and germ cells, Mansuy suggests.

One of the outstanding questions in the field is why epigenetic inheritance only lasts for a handful of generations and then stops, said Eric Greer, an epigeneticist at Harvard Medical School and Boston Childrens Hospital who studies the epigenetic inheritance of longevity and fertility in C. elegans. It appears to be a regulated process, in part because the effect persists at the same magnitude from one generation to the next, and then abruptly disappears. Moreover, in a paper published in Cell in 2016, Rechavi and colleagues described dedicated cell machinery and specific genes that control the duration of the epigenetically inherited response. So its an evolved mechanism that likely serves many important functions, Rechavi said.

But what exactly is adaptive about it? If the response is adaptive, why not hardwire it into the genome, where it could be permanently and reliably inherited?

In Murphys C. elegans model, because the learned avoidance behavior is transient (even if it is transgenerational), it allows animals to go back to eating bacteria that are nutritious but smell a lot like those pathogens, she explained. Sniffing out the difference between food and foes can be difficult, so worms that permanently avoid pathogens will miss out on nutritious food sources.

Greer concurs that there could generally be a cost to deploying an adaptive response permanently. For example, deploying antiviral defenses when pathogens arent around is a waste of resources that could be used instead for growth and reproduction.

Trade-offs could also constrain other adaptations. In Burtons 2017 study, worms exposed to P. aeruginosa produced offspring resistant to the pathogen, but that adaptation was deleterious to the offsprings ability to respond to other challenges, like osmotic stress. Unavoidable trade-offs between adaptations to different stresses make it impossible for the worms to be optimally adapted across the board.

In that scenario, you wouldnt want it hardwired into your genetics. Youd want this plasticity where you could program the adaptation, but also get rid of it, Burton explained. That may explain why stress appears to reset transgenerational small-RNA inheritance, as reported by Rechavi and his colleagues in a new preprint on biorxiv.org.

Very little work has been done to investigate mismatched stresses between parents and offspring, but a lot of literature suggests that these mismatched stresses might play a role in human diseases, Burton said. I think mechanistically looking at that is going to be really interesting, going forward.

Correction added on Oct. 16, 2019: The beginning of one sentence was rephrased to clarify that the described work in Murphys lab was not related to Rechavis experiments.

Read the original:
Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine

Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) – MS Wkly

As Biotechnology companies, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Table 1 highlights Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s net margins, return on equity and return on assets.

Liquidity

The Current Ratio of Brainstorm Cell Therapeutics Inc. is 1 while its Quick Ratio stands at 1. The Current Ratio of rival Magenta Therapeutics Inc. is 17.1 and its Quick Ratio is has 17.1. Magenta Therapeutics Inc. is better equipped to clear short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

In next table is given Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s ratings and recommendations.

Brainstorm Cell Therapeutics Inc. has a 126.70% upside potential and an average price target of $9.

Institutional & Insider Ownership

Institutional investors owned 11.4% of Brainstorm Cell Therapeutics Inc. shares and 85.4% of Magenta Therapeutics Inc. shares. 0.6% are Brainstorm Cell Therapeutics Inc.s share owned by insiders. Comparatively, 2.2% are Magenta Therapeutics Inc.s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc.s stock price has smaller growth than Magenta Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read this article:
Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly

Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights – P&T…

FELTON, California, Oct. 7, 2019 /PRNewswire/ -- The global Stem Cell Market was valued at US$ 8.65 billion in 2018 and is estimated to grow at an 8.8% CAGR and will touch the value of US$ 15.63 Billion by the completion of the year 2025.

During the previous insufficient years, stem cells therapy has been attaining grip all over the world. A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years. Moreover, the growing investment by community along with private groups for research actions are expected to increase the general development of the market during the nearby future.

Classification:

The global stem cell market can be classified by Therapy, Technology, Application, Product End User, and Region. By Therapy it can be classified as Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy. The subdivision of Autologous Stem Cell therapy was the leading sector by means of generation of income in 2018. It is credited to big scale ingestion of these products owing to associative high compatibility. Furthermore, growing methodical evaluations and meta-analysis revisions on reviewing the efficiency of autologous cell therapy on treatment of lower limb illnesses will more offer thrust to the market.

By Technology it can be classified as Expansion and Sub-Culture, Cryopreservation, Cell Production, Cell Acquisition. The subdivision of Cell Acquisition technology is the elementary main step that has caused supremacy of this section. It is likely to uphold this position during the course of the forecast period, due to increasing alertness about the importance of stem cells. Bone marrow is the maximum utilized technology for cell acquisition due to the comparatively quicker manufacture of new cells from bone marrow. Additionally, cells that initiate from bone marrow are extra concentrated as equated to additional origin places.

Get Sample PDFand read more details about the "Stem Cells Market" Report 2025.

By Application it can be classified as Drug Discovery and Development, Regenerative Medicine. The subdivision of Regenerative Medicine is witnessed to grasp the prospective for creating early-intervention treatments to treat degenerative illnesses and painful injury. Additionally, obtainability of regenerative medicine through a widespread variety of clinical areas is motivating the development of the section.

By Product it can be classified as Very Small Embryonic like Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, and Adult Stem Cells. The subdivision of Adult Stem Cell detained the biggest share of the market which was prized US$ 7.38 billion in 2018. It is projected to carry on leading for the duration of the forecast. This is credited to the low-slung hazards of pollution associated to sub-culturing, negligible necessity of labor force for production and compatibility with humanoid figure. By End User it can be classified as Service Companies, Cell and Tissues Banks, Tools and Reagent Companies, Therapeutic Companies.

Regional Lookout:

By Region, the global stem cells industry can be classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to record speedy CAGR for the duration of the forecast. The nations such as Singapore, Australia, and Japan are mainly capitalizing in the R&D projects. This is set to motivate the development of the region. Economies from Asia Pacific are likely to be at the front position of speedily developing cell industry. Issues similar to advantageous controlling strategies together with openings for commercialization increase the provincial growth. Controlling alterations relating to regenerative medication in Japan have fascinated worldwide companies to capitalize in the Japanese market.

North America is expected to carry on holding the foremost market share during the period of forecast, due to the hard work from government and private segments operational in the direction of formation of distinct business models in Canada and the U.S.A.

Companies:

The companies are opting for multidisciplinary commercial growth and multi-sector team work to safeguard incessant source of great quality pluripotent and distinguished cells. This is set to step up the rivalry, motivating the continuous necessity to present innovative products.

Some of the important companies for stem cell market are Promethera Biosciences, Human Longevity Inc., Cytori Therapeutics, BIOTIME, INC., STEM CELL Technologies Inc., Mesoblast, Cynata, Advanced Cell Technology Inc., Osiris Therapeutics Inc., and Celgene Corporation.

Browse 190 page research report with TOC on "Global Stem Cells Market" at: https://www.millioninsights.com/industry-reports/stem-cells-market

Market Segment:

Browse reports of similar category available with Million Insights:

About Million Insights:

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place that will enable you to compare data points, before you make a purchase. Enabling informed buying is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact:

Ryan ManuelResearch Support Specialist, USAMillion InsightsPhone: 1-408-610-2300Toll Free: 1-866-831-4085Email: sales@millioninsights.comWeb: https://www.millioninsights.com/Blog: http://www.millioninsights.blogspot.com/

See the original post here:
Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T...

New Tools in the Works to Probe Adult Human Neurogenesis – The Scientist

In March 2018, researchers reported evidence suggesting that adult humans do not generate new neurons in the hippocampusthe brains epicenter of learning and memory. The result contradicted two decades of work that said human adults actually do grow new neurons there, and revealed a need for new and better tools to study neurogenesis, Salk Institute President Fred Gage, who generated foundational evidence for adult human neurogenesis, told The Scientist at the time.

Since that study was published, several other teams have used similar techniquesbut have come to different conclusions, publishing evidence that adult humans do indeed grow new hippocampal neurons, even at the age of 99. Despite the equivocal results, Maura Boldrini, a neuroscientist at Columbia University, and a number of other neuroscientists tell The Scientist they think neurogenesis does occur in the adult human brain, bolstering learning and memory and possibly also our stress and emotional responses.

Neurogenesis is fundamentally important for the brain to react to all sorts of different insults and prevent neurological and psychiatric problems, Boldrini says. Because of its role in brain function, researchers want to learn how neurogenesis works to potentially use it to treat brain trauma, neurodegeneration, psychiatric disorders, such as depression, and possibly even the ill effects of aging.

The growth of new neurons is well studied in newborn and adult animals, especially rodents. Theres prolific neurogenesis as the brain develops, which then drops off and plateaus in adulthood, only occurring in particular areas of the brain. Examinations of human postmortem tissue suggest that the process is similar in people, based on antibody markers that label neural progenitors and young neurons. But those signals can be hard to detect in preserved cells, and the gap in time between the death of a donor and when her tissue is fixed and analyzed can affect the reliability of the markers, scientists say, which might explain the disparities in findings between different studies.

To get a reliable picture of the extent of neurogenesis in adults, scientists are pursuing a variety of new tools. Combining the direct detection techniques, such as RNA sequencing, with indirect ones, such as fMRI, Boldrini says, will indicate whats actually real when it comes to the human brains ability to make new neurons.

In a recent study, Boldrini and colleagues found that the dentate gyrus, a region of the hippocampus where neurogenesis occurs, is bigger in people who were more resilient to early life stresses, such as abuse or separation from their parents. They have more cells in the region, more neurons, and probably more neurogenesis, she says.

Of course, Boldrini notes, the study has limitations. She and colleagues were working with tissue from deceased patients brains, which brings with it the challenges of preservation and the limitations of studying dead cells. Studies in postmortem tissue have made it extremely difficult to assess whether treatments, especially in psychiatric disorders, are effective, Boldrini explains. Thats why colleagues in her department and in other labs around the world have been working to develop fMRI as a way to track neural changes that correlate with neurogenesis-related network activity in living patients.

Neurogenesis is fundamentally important for the brain to react to all sorts of different insults and prevent neurological and psychiatric problems.

Maura Boldrini, Columbia University

She and colleagues, for example, are tracking how different regions of the hippocampus in patients with depression connect with other brain regions before and after antidepressant treatment. The measurements, though, are indirect, so if the team sees increased connectivity, it cannot immediately conclude there is increased neurogenesis. You can say there is increased plasticity, Boldrini explains, which could be formed by dendrite sprouting or the making of new neurons. The same is true if the region grows in volume, which could be caused by an increase in blood capillaries or, again, the growth of new neurons. Whats generating the change cant be teased out of the results, she explains.

Studies in adult rodents have used MRI to visualize the migration of neural stem cells in the brain, but those need to be labeled with MRI contrast agents that are directly injected into neurogenic regions, a technique not suitable to use in humans.

Magnetic resonance spectroscopy, however, is non-invasive and measures biochemical changes in the body and brain. Scientists say they think it could give them a clue to how neurogenesis works in living humans, if they could identify a biomarker specific to neural stem cells or neural progenitor cells. In 2007, a team announced it had identified a metabolic biomarker that they could detect in living animals, and possibly in living humans, to track neurogenesis in vivo. That would certainly be very attractive to follow how the extent of neurogenesis is affected in an individual over time or for example in response to disease or medication, Jonas Frisn, a molecular biologist and stem cell scientist at the Karolinska Institute in Sweden, writes in an email to The Scientist. However, he says, that study has been difficult to reproduce, and that field has not taken off at all yet, unfortunately.

Another option in the works is PET imaging, a technique Yosky Kataokas team at the RIKEN Institute has been working on to identify new neuronal growth in living people. Three years ago, he and colleagues reported successfully tracking the proliferation of new cells in the neurogenic regions of rat brains using the PET tracer 3-deoxy-3-[18F]fluoro-l-thymidine and a drug called probenecid. The drug is a treatment for gout that appears to enhance the ability of the tracer to cross the blood-brain barrier. The tracer and drug together allowed the researchers to image the dentate gyrus and the subventricular zone, the two regions in adult rodents brains where neurogenesis takes place, and quantitatively visualize the neurogenic activity in the animals. The team says it is now testing the technique in adult non-human primates, with the intent to eventually use it in humans.

With PET, the challenge is to find a tracer small enough that it can be injected in the blood, pass the blood-brain barrier, and get to the brain to attach to some specific molecule that is stem-cell specific, Boldrini says. We are still trying to find markers that are stem-cell specific.

Identifying such specificity requires a more in-depth investigation of neural stem cells. The brain has tremendous heterogeneity, many, many different cell types. And if you dont look at every single cell type, you cant appreciate the complexity and heterogeneity of the brain, says Hongjun Song, a neuroscientist at the University of Pennsylvanias Perelman School of Medicine. Even the same cell type, he notes, can be in different states, so, for example, neural stem cells can be in an active state, proliferating rapidly and developing into new neurons, or a dormant state, rarely dividing and when they do, remaining as stem cells. Despite their distinct activities, cells in these different states may still express the same marker proteins, making them difficult to differentiate without single-cell analysis, such as single-cell RNA sequencing.

A three-dimensional reconstruction of nine cubic millimeters of mouse hippocampus, a part of the brain involved in memory, profiled with Slide-seq. Different cell types are shown in red, green, and blue.

Chen and Macosko labs, courtesy of Broad Institute of MIT and Harvard

The question I think were all interested in in the human brain is, do we really have cells with stem cell properties or immature neurons? I think theres probably less of a debate about whether we have those cells or not, Song says. The question is . . . are they the same as in rodents or are they very different than in rodents? Single-cell sequencing will allow us to get that kind of unbiased view.

Isolating neuronal precursor cells in the human brain isnt easy. Its much different than doing it in rodents, Song explains. In animals brains, researchers can label neuronal stem cells when the rodent is alive, and later extract and study those cells with RNA sequencing, which he and colleagues did in 2015, revealing the transcriptomes of neural stems and the cells they mature into in the adult mouse hippocampus. In humans, however, researchers again have to work with postmortem brain tissue and cant label the cells while a patient is alive. Instead, scientists have to go cell-by-cell looking for neural progenitors. The human brain, Song adds, is much larger than the mouse brain, so the cells are sparser and farther apart. You have to go through many, many cells to find them in humans, Song says.

His team and others, including Boldrinis and Frisns, have been working on RNA sequencing in postmortem human brains for several years now, and Boldrini says a new technique developed by Harvard University and MIT scientists in March might help with sorting human hippocampal nerve cells. Called Slide-seq, the technique uses genetic sequencing to draw 3-D tissue maps that identify a cells type, function, and location in tissue samples. So far, its only been tested on mouse tissue, but may hold promise for studying neural stem cells and newly made neurons, Boldrini says.

Ashley Yeager is an associate editor atThe Scientist. Email her at ayeager@the-scientist.com.

Read this article:
New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist

Follow the lead of Aston Villa players and become a blood stem cell donor – 7500 To Holte

Aston Villa are a source of pride for many of us. Whether we have been life long fans or if it isa more recent obsession; once Villa grabs hold of you, it doesnt let go. The club has the history to back this up; looking at William McGregors statue and thinking about his achievements in helping setting up the league, the beauty of the Holte End and the quotes of the commentary from the European Cup win in 82 we know it has a well spring to draw on to bring pride.

Anyone with access to Facebook, Instagram or Youtube also know that the social media section of the club draw on this freely. A bombardment of hashtag #partofthepride, images of Rotterdam and videos about the club encourage us to belong, whether the club deserves it or not with its on field performances.

However the club has done something that has made me proud to be a Villan. It has led the way in a community venture which has made me live up to the clubs overused hashtag. On Saturday 20th September the club blitzed its social media with Finns story to tie in with World Bone Marrow Donor Day.

It is about a child who has a genetic disorder which causes HLH, hemophagocytic lymphohistiocytosis (lets not say that again) which affects a childs brain and body where its own white cells are attacking itself and if not treated will lead to death. This requires a Bone Marrow transplant to recover from the illness. Villa has linked up with DKMS who registered Tyrone Mings, Jack Grealish, Neil Taylor, Tom Heaton and others. They have been shown to have a simple cheek swab which takes 3 minutes and has registered the players to the world ide Bone Marrow register and encourage others to do the same.

And this is the source of my pride in Villa. I love supporting the club, sharing moments where we celebrate last minute goals, moments of individual brilliance, mocking the Blues and getting angry at being robbed or frustrated at poor performance. However Villa has given me another reason to be proud; it has lead the way in getting people signed up for the Bone Marrow Register. By doing this Villa has show it can be a club doing something for the community, for others rather than being the clich of overpaid players just in it for the money. I want to support a club that helps all of us fans support other and help other people; Villa have shown they can come up to my expectations.

I do have a vested interest in this as my daughter Isobel (the Griscelli Supergirl) also has HLH and has had for three years. She has been under Birmingham Childrens Hospital care and will need a bone marrow transplant at some point too. So thank you Villa for leading on this; I hope the Premier League, Championship and EFL all follow our example and players and fans will sign up with DKMS at events or apply on line for a kit.

If every adult fan who attended Villa Park signed up that could be tens of thousands of people who could be potential matches for Finn, Isobel or others from all over the world who need a Bone Marrow Match. Lives can be saved in that simple, 3 minute act. If all the Villans who could join, joined we would add thousands to the 27.5 million that are already on the register. The link up between DKMS and Villa could be force for good that could give exponentially.

Im Kevin and you can find me @snoggyfrokel - So please sign up via the DKMS website https://dkms.org.uk/en/register-now in the UK or for worldwide fans search for DKMS as they are in most countries.

Like our club has proved, like we prove as fans of this club #YouveGotItInYou

Originally posted here:
Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte